BioSpace News Archive

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), today announced financial results for the full year ended December 31, 2020 and provided corporate updates.

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI-driven preventative health business is pleased to announce a co-exclusive production and distribution rights and license agreement (‘Agreement’) with US-based Infinity BiologiX LLC (‘IBX’), a leading central laboratory providing sample collection and processing,

Phase 1 clinical study report for Voriconazole Inhalation Powder indicated no treatment emergent adverse events at peak plasma levels for Invasive Pulmonary Aspergillosis Phase 1 Single Ascending Dose study of Tacrolimus Inhalation Powder met and exceeded therapeutic drug levels with a single dose with no significant adverse events reported

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. The acquisition provides Gilead with Hepcludex ® (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults

Best-in-class, guided risk analysis and structured data management enable medical device companies to develop safe, regulatory-compliant products

Quibim, a global leader in whole-body medical imaging analysis, announced the launch of qp-Prostate, its latest and most advanced prostate AI based Magnetic Resonance solution, after receiving 510 clearance by the US Food and Drug Administration.

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery device designed to lower eye pressure for open-angle glaucoma patients, announced the first-ever release of five-year follow-up data from its HORIZON pivotal trial.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today preclinical results and filing of a patent covering the use of manipulated cord blood derived monocytes for prevention of suicidal ideations as well as inflammation of the brain.

Contentsquare, the leading experience analytics company, is partnering with leaders in the pharmaceutical and biotech sector to help manage the accelerated shift to digital healthcare.

Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it will host a Key Opinion Leader (KOL) Perspectives webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice on Wednesday, March 10, 2021 at 10:00am Eastern Time.